Most Read Articles
Yesterday
Routinely used for treating cardiovascular diseases, statins have been shown to benefit other conditions, and new evidence suggests that using the drug at high intensity reduces the risk of hip or knee replacement, an effect that may be specific to rheumatoid arthritis.
Pearl Toh, 29 Jun 2020
Having migraine during midlife appears to be associated with a higher risk of developing dementia in later life, according to a large population-based longitudinal Danish study presented at the AHS* 2020 Virtual Meeting, indicating that migraine may be a risk factor for dementia.
30 Jun 2020
Patients with psoriatic arthritis (PsA) often suffer from liver abnormalities, which are associated with higher body mass index (BMI), daily consumption of alcohol, more severe disease, and some therapies, according to a recent study.
Christina Lau, 5 days ago

Pembrolizumab in combination with chemotherapy significantly improves progression-free survival (PFS) vs chemotherapy alone in patients with previously untreated, locally recurrent inoperable or metastatic triple-negative breast cancer (TNBC), results of the KEYNOTE-355 study have shown.

New oral therapies for adolescents with HCV more cost-effective than PR strategy

21 Jun 2020
Authorities in Malaysia have approved a compulsory license for Hepatitis C treatment, which allows for cheaper generic medication to be produced without the drug patent holder’s consent.

Novel oral regimens for adolescents with hepatitis C virus (HCV) appears to be cost-effective compared with pegylated interferon α with ribavirin (PR) therapies, but only in the context of China and the US, suggests a recent study.

This analysis sought to assess the cost-effectiveness of oral regimens relative to that of PR strategies in adolescents in the US and China.

The investigators developed a Markov model to measure the economic and health outcomes of ledipasvir/sofosbuvir (LS) for genotypes 1 and 4, sofosbuvir/ribavirin (SR) for genotype 2, and ledipasvir/sofosbuvir/ribavirin (LSR) for genotype 3 HCV infection compared with the outcomes of PR treatment. They obtained clinical costs and utility inputs from published sources.

The following outcomes were measured: lifetime discounted quality-adjusted life years (QALYs), costs, and incremental cost-effectiveness ratios (ICERs). One-way and probabilistic sensitivity analyses facilitated the uncertainty.

In the US, the ICERs of LS treatment were $14,699/QALY for genotype 1 HCV infection and $14,946/QALY for genotype 4 in comparison to the PR strategy. Additionally, the ICER of SR strategy was $42,472/QALY for genotype 2, while that of LSR was $49,409/QALY for genotype 3.

In the Chinese context, LS for genotypes 1 and 4, SR for genotype 2, and LSR for genotype 3 were the major alternative treatments to the PR strategy. Of note, these results were robust to sensitivity analyses.

“Novel oral regimes have been approved for treating HCV infection in adolescents due to their superior effectiveness and safety,” the investigators noted.

Digital Edition
Asia's trusted medical magazine for healthcare professionals. Get your MIMS Doctor - Malaysia digital copy today!
Sign In To Download
Editor's Recommendations
Most Read Articles
Yesterday
Routinely used for treating cardiovascular diseases, statins have been shown to benefit other conditions, and new evidence suggests that using the drug at high intensity reduces the risk of hip or knee replacement, an effect that may be specific to rheumatoid arthritis.
Pearl Toh, 29 Jun 2020
Having migraine during midlife appears to be associated with a higher risk of developing dementia in later life, according to a large population-based longitudinal Danish study presented at the AHS* 2020 Virtual Meeting, indicating that migraine may be a risk factor for dementia.
30 Jun 2020
Patients with psoriatic arthritis (PsA) often suffer from liver abnormalities, which are associated with higher body mass index (BMI), daily consumption of alcohol, more severe disease, and some therapies, according to a recent study.
Christina Lau, 5 days ago

Pembrolizumab in combination with chemotherapy significantly improves progression-free survival (PFS) vs chemotherapy alone in patients with previously untreated, locally recurrent inoperable or metastatic triple-negative breast cancer (TNBC), results of the KEYNOTE-355 study have shown.